Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer 1Q Revenues up 45% Driven by COVID Vax | Contract Pharma

What are you searching for?

Sign in
Financial News

Pfizer 1Q Revenues up 45% Driven by COVID Vax

Vaccine sales were $4.9 billion in the quarter, with BNT162b2 contributing $3.5 billion in global revenues.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
1Q Revenues: $14.6 billion (+45%)
1Q Earnings: $4.9 billion (+45%)
Comments: Vaccines sales were $4.9 billion in the quarter, up from $1.6 billion in 1Q20 driven by BNT162b2, which contributed $3.5 billion in global revenues. Excluding BNT162b2, revenues grew 8%. Eliquis revenue was up 25% operationally to $1.6 billion. Oncology sales were up 18% to $2.9 billion. Internal Medicine sales were up 11% to $2.6 billion. Hospital sales were up 12% to $2.3 billion. Inflammation & Immunology sales were up 9% to $1.1 billion. Rare Disease revenues were up 29% to $824 million. Vyndaqel/Vyndamax globally was up 88% to $453 million. Xeljanz globally was up 18% to $538 million. Xtandi sales were up 28% to $267 million. Inlyta globally was up 34% to $229 million. Biosimilars, which grew 79% to $530 million. Prevnar 13 sales were $1.3 billion, down 11%, primarily driven by a 57% decline due to disruptions to wellness visits due to COVID-19, including delaying other vaccinations. Ibrance sales were down 1% to $1.3 billion. Chantix sales were down 21% to $217 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters